A Phase I Proof-of-Concept Study of CBL0137 Combined with Ipilimumab and Nivolumab Therapy in Locally Advanced or Metastatic Melanoma
A Phase I Proof-of-Concept Study of CBL0137 Combined with Ipilimumab and Nivolumab Therapy in Locally Advanced or Metastatic Melanoma
批准号:
10722873
负责人:
Igor Astsaturov
金额:
$26.37万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-07-01 至 2025-06-30
关键词:
Automobile DrivingBindingBiologicalBiopsyBlood specimenBypassCell NucleusCellsClinicalClinical OncologyClinical TrialsCombination immunotherapyCoupledDataDouble-Stranded RNAFibroblastsHumanImmune responseImmunityImmunofluorescence ImmunologicImmunologic AdjuvantsImmunologicsImmunosuppressionImmunotherapyIn SituInflammatoryInflammatory ResponseInfluenzaInformaticsInnate Immune ResponseInterferon Type ILeftMalignant - descriptorMalignant NeoplasmsMetastatic MelanomaMetastatic/RecurrentMindMyeloid-derived suppressor cellsNatural Killer CellsNeoadjuvant TherapyNivolumabNuclearNuclear ProteinPathway interactionsPatientsPharmaceutical PreparationsPhasePhase I Clinical TrialsPre-Clinical ModelProteinsRIPK3 geneRNARNA BindingRefractoryResistanceSafetySignal TransductionSolid NeoplasmT cell infiltrationTestingTissue SampleTumor AntigensValidationViralVirusVirus DiseasesVirus ReplicationWorkZ-Form DNAanti-canceranti-tumor immune responsecancer clinical trialcancer immunotherapycell typeexperiencefeasibility trialimmune checkpoint blockadeimmunogenicimmunogenicityinfluenza infectioninfluenzavirusinsightintravenous administrationipilimumabmelanomamimeticsmouse modelnovelresponsesensorsmall moleculesynergismtranscriptomicstranslational oncologytumortumor microenvironmenttumor-immune system interactionsviral detection
中文摘要
项目总结/文摘
英文摘要
PROJECT SUMMARY/ABSTRACT
This proposal will investigate a novel small-molecule strategy as a means to activate necroptosis, overcome the
immunosuppressive tumor microenvironment (TME) and rekindle immune checkpoint blockade (ICB)
responsiveness of human solid tumors. Our recent work with influenza virus (IAV) has outlined a new pathway
of nuclear necroptosis. Nuclear necroptosis during IAV infections is initiated when the host sensor protein ZBP1
detects viral Z-RNA (left-handed dsRNA) and triggers RIPK3-dependent necroptosis from the nucleus, releasing
nuclear “danger signals” (DAMPs and alarmins), and driving a potent inflammatory response. But what is
deleterious in severe influenza may be beneficial for cancer immunotherapy, because triggering inflammatory
nuclear necroptosis in the TME is an attractive way to make a cold tumor hot. We have discovered a compound
(CBL0137) which activates ZBP1 and potently reverses ICB unresponsiveness in mouse models of melanoma.
CBL0137 activates ZBP1 by inducing Z-DNA formation in cells, bypassing need for active virus replication.
Here, we propose to test the combination of CBL0137+nivolumab/ipilimumab in a small feasibility trial in patients
with locally advanced and metastatic melanoma, a tumor type in which ICB has shown great promise, but where
unresponsiveness remains a significant problem. We hypothesize that that induction of necroptosis with
CBL0137 in combination with immunotherapy will not only invigorate the anti-melanoma immune response to
ICB, but will also overcome the resistance conferred by CAFs and MDSCs in the melanoma TME. We propose
two Aims to test this hypothesis:
Aim 1. Conduct a proof-of-concept clinical trial to examine the feasibility of CBL0137+ICB (nivolumab
and ipilimumab) in melanoma. This Aim will establish whether intravenous administration of CBL0137 is safe
and tolerated in the setting of the frontline immunotherapy by combining CBL0137+nivolumab/ipilimumab in
locally advanced and metastatic melanoma.
Aim 2. Elucidate the biological effects of neoadjuvant CBL0137+ICB in melanoma patients. We will
systematically analyze on-treatment biopsies: (1) to evaluate Z-DNA formation and necroptosis activation in the
melanoma TME; and (2) to characterize treatment-induced changes in both malignant and reactive cell types
(e.g., CAFs and MDSCs) in the melanoma TME, using in situ spatial transcriptomics and immunofluorescence
approaches, each coupled with cutting edge informatics. These studies will provide unprecedented mechanistic
insight into the effects of CBL0137 on the tumor stroma during ICB therapy.
A team of experts in clinical and translational oncology (Olszanski, Astsaturov), and necroptosis and immunity
(Balachandran) will lead the proposed studies. This concept will establish CBL0137 synergy with ICB and will
open an entirely new range of opportunities for using this necroptosis-activating ‘virus mimetic’ as a means to
make immunologically cold tumors hot.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Neoadjuvant Stroma Modification in Pancreatic Cancer
-
批准号:10199321
-
项目类别:
-
资助金额:$21.05万
-
财政年份:2021
-
负责人:Igor Astsaturov
-
依托单位:
Neoadjuvant Stroma Modification in Pancreatic Cancer
-
批准号:10459402
-
项目类别:
-
资助金额:$24.91万
-
财政年份:2021
-
负责人:Igor Astsaturov
-
依托单位:
Oncogenic Synapses: cell-cell contacts enabling trogocytic-based metabolic interactions between pancreatic cancer and fibroblastic stromal cells
-
批准号:9894770
-
项目类别:
-
资助金额:$20.05万
-
财政年份:2019
-
负责人:Igor Astsaturov
-
依托单位:
Synergistic targeting of cholesterol metabolism and EGFR signaling in cancer
-
批准号:9335800
-
项目类别:
-
资助金额:$37.97万
-
财政年份:2014
-
负责人:Igor Astsaturov
-
依托单位:
Synergistic targeting of cholesterol metabolism and EGFR signaling in cancer
-
批准号:8930103
-
项目类别:
-
资助金额:$37.04万
-
财政年份:2014
-
负责人:Igor Astsaturov
-
依托单位:
Synergistic targeting of cholesterol metabolism and EGFR signaling in cancer
-
批准号:8837225
-
项目类别:
-
资助金额:$37.04万
-
财政年份:2014
-
负责人:Igor Astsaturov
-
依托单位:
Targeting Sterol Gene SC4MOL and EGFR as Synergistic Anti-Cancer Strategy
-
批准号:8723411
-
项目类别:
-
资助金额:$19.6万
-
财政年份:2013
-
负责人:Igor Astsaturov
-
依托单位:
Regulation of EGFR by SC4MOL- and NSDHL-Dependent Trafficking
-
批准号:8537870
-
项目类别:
-
资助金额:$21.9万
-
财政年份:2012
-
负责人:Igor Astsaturov
-
依托单位:
Regulation of EGFR by SC4MOL- and NSDHL-Dependent Trafficking
-
批准号:8223653
-
项目类别:
-
资助金额:$19.41万
-
财政年份:2012
-
负责人:Igor Astsaturov
-
依托单位:
Targeting Sterol Gene SC4MOL and EGFR as Synergistic Anti-Cancer Strategy
-
批准号:8293041
-
项目类别:
-
资助金额:$19.71万
-
财政年份:2011
-
负责人:Igor Astsaturov
-
依托单位:
Targeting Sterol Gene SC4MOL and EGFR as Synergistic Anti-Cancer Strategy
-
批准号:8165559
-
项目类别:
-
资助金额:$19.92万
-
财政年份:2011
-
负责人:Igor Astsaturov
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: